cobicistat + osimertinib

This is a combination therapy of cobicistat, a potent cytochrome P450 3A (CYP3A) inhibitor, and osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Osimertinib is used for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Cobicistat acts as a pharmacokinetic booster by inhibiting CYP3A-mediated metabolism of osimertinib, thereby increasing its plasma concentration in patients who have subtherapeutic levels of the drug. This approach aims to enhance the effectiveness of osimertinib without increasing toxicity. The combination has been studied in clinical trials for NSCLC patients with low steady-state trough concentrations of osimertinib[1][2][4].

Other names

cobicistat and osimertinibosimertinib boosted with cobicistat